MRI-targeted biopsy: is systematic biopsy obsolete?
Dordaneh Sugano1, Abhinav Sidana1,2, Brian Calio1, Kaitlan Cobb1, Baris Turkbey3, Peter A. Pinto1
Canadian Journal of Urology, Vol.24, No.4, pp. 8876-8882, 2017
Abstract Introduction: Although prostate cancer is the most common non-cutaneous cancer in men, it is traditionally diagnosed with a non-targeted, systematic transrectal ultrasound prostate biopsy (TRUS-Bx). This technique has been demonstrated to both under-detect clinically significant (CS) cancer and over-detect clinically insignificant cancer, and performs poorly in patients with a prior negative biopsy. With recent advances in MRI technology, most prominently the advent of multiparametric MRI, MRI-targeted prostate biopsy (MRI-TB) has been gaining favor as a more accurate alternative to TRUS-Bx. In this review, we attempt to summarize the current literature on MRI-TB and to determine if… More >